聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的病毒学应答

Virological Response of Chronic Hepatitis C Management with Peg-interferon α-2b and Ribavirin

目的研究聚乙二醇干扰素α-2b(PEG-IFNα-2b)联合利巴韦林治疗慢性丙型肝炎的病毒学应答情况。方法回顾性分析40例接受抗病毒治疗的慢性丙型肝炎不同基因型患者的临床资料,根据患者体重给予剂量个体化的PEG-IFNα-2b和利巴韦林,hepatitisCvirus-1型感染者治疗48周,非HCV-1型感染者治疗24周。分别在治疗前、治疗后12周、治疗结束时及治疗结束24周后测定患者血浆HCVRNA水平。结果HCV-1型感染者24例(60.0%),非HCV-1型感染者16例(40.0%);HCV-1型和非HCV-1型患者早期病毒学应答(EVR)率分别为75.0%(18/24例)和87.5%(14/16例),治疗终点病毒学应答(ETVR)率分别为80.0%(16/20例)和85.7%(12/14例),持久病毒学应答(SVR)率分别为56.2%(9/16例)和78.5%(11/14例)。结论基于患者体重的剂量个体化PEG-IFNα-2b联合利巴韦林可有效治疗不同基因型慢性丙型肝炎。

Objective To evaluate the virological response of managing chronic hepatitis C （ C HC ） with peg-interferon α-2b （ PEG-IFN α-2b） and ribavirin. Methods We retrospectively analyzed the virological response of 40 patients with different genotypes of hepatitis C virus （HCV） infection after anti-HCV management. Patients were given different dosages of PEG-IFN α-2b and ribavirin based on their weights. The duration of treatment was 48 weeks for patients infected by HCV genotype 1, and was 24 weeks for the others. HCV RNA was tested before treatment, 12 weeks post management, end of treatment, and 24 weeks after treatment stopped. Results Data from 40 patients were collected. Among them, 24 cases experienced HCV genotype 1 infection, and 16 cases were infected with other genotypes. Between these two groups, the early virological responses were 75.0% （18/24） and 87.5% （14/16） , the end-of-treatment virological responses were 80. 0% （16/20） and 85.7% （12/14） , and the sustained virological responses were 56.2% （9/16） and 78.5% （11/14）, respectively. Conclusion Body weight-based customized PEG-IFN α-2b in combination with ribavirin can effectively treat patients with different genotypes of CHC.